DRAFT GUIDELINE EMA ON MEDICINAL PRODUCTS CONTAINING GENETICALLY MODIFIED CELLS

The EMA published for public consultation a guideline on quality, non-clinical and clinical aspects of medicines containing genetically modified cells, including CAR-T cell and stem cell products. Share your thoughts by using the template linked in the guideline. Deadline is 31 July 2019.

copyright 2016 BVWB-ABBT | All Rights Reserved